Search - tctmd.com

Displaying 101 - 120 of 191

Sort: Relevancy | Date

Presentation

Implantation of Everolimus-Eluting Bioresorbable Scaffolds in a Diabetic All-Comers Population

Presenter: Jens Wiebe

August 26, 2015

News Daily News

RIBS IV: EES Surpass DCB for Treatment of In-Stent Restenosis

L.A. McKeown

July 01, 2015

News Industry News

U.S. to vie with India for top bioabsorbable stent market after FDA approval

June 25, 2015

News Daily News

La Anchura del Filamento de los BRS se asocia a Más IM Perioperatorios

June 02, 2015

News Daily News

BRS支柱与围手术期心梗增加有联系

June 02, 2015

News Daily News

BRS Strut Width Tied to Increased Periprocedural MI

June 02, 2015

News Daily News

积极准备下钙化灶 BRS 置入可行

April 29, 2015

News Daily News

Uso Viable de BRS en Lesiones Calcificadas Con Preparación Agresiva

April 29, 2015

News Daily News

BRS Use in Calcified Lesions Feasible With Aggressive Preparation

April 29, 2015

News Daily News

EVERBIO II Published: BVS Matches Leading DES for Midterm Outcomes

L.A. McKeown

February 26, 2015

Presentation BRS 2015

BIORESORBABLE VASCULAR SCAFFOLDS A One-day Case-based Technique-oriented Course: A Case with Vessel and - or Lesion Tortuosity

Presenter: Antonio L. Bartorelli

February 10, 2015

Presentation

Beyond the Early Stages: Insights from the ASSURE Registry on Bioresorbable Vascular Scaffolds

Presenter: J. W?hrle

December 21, 2014

News Daily News

ASSURE Registry: Angiographic, Clinical Outcomes of BRS Similar to DES at 1 Year

L.A. McKeown

December 21, 2014

News Daily News

OCT Study Suggests Plaque ‘Capping’ Safer With BRS Than BMS

November 06, 2014

Presentation TCT 2014

Con: The Psychological Attraction Will Pass When the Data Emerges!

Presenter: Daniel I. Simon

September 16, 2014

Presentation TCT 2014

Pro: Within 10 Years, Most Coronary Intervention Will Use BRS!

Presenter: Stephan Achenbach

September 16, 2014

Presentation TCT 2014

TCT 612: Clinical Outcomes in Patients with Calcified Lesions Treated with Bioresorbable Vascular Scaffolds

Presenter: Dariusz Dudek, Pieter C. Smits, Vincent On-Hing Kwok, Vasileios Panoulas

September 16, 2014

Presentation TCT 2014

Status of DCB for PVD and Lessons Learned from the Recent FDA Panel

Presenter: Andrew Farb, Mitchell W. Krucoff, Aaron V. Kaplan, Juan F. Granada

September 16, 2014

Presentation TCT 2014

TCT 611: Multimodality Assessment 12 Months After Implantation of a Bioresorbable Scaffold for the Treatment of Culprit Lesions in Myocardial Infarction

Presenter: Dariusz Dudek, Pieter C. Smits, Vincent On-Hing Kwok, Ulrich Hink

September 16, 2014

Presentation TCT 2014

The Emphatic Case for OPCs NOW for New DES Approval in the United States!

Presenter: Andrew Farb, Mitchell W. Krucoff, Aaron V. Kaplan, Laura Mauri

September 16, 2014

Advertisement

Implantation of Everolimus-Eluting Bioresorbable Scaffolds in a Diabetic All-Comers Population

RIBS IV: EES Surpass DCB for Treatment of In-Stent Restenosis

U.S. to vie with India for top bioabsorbable stent market after FDA approval

La Anchura del Filamento de los BRS se asocia a Más IM Perioperatorios

BRS支柱与围手术期心梗增加有联系

BRS Strut Width Tied to Increased Periprocedural MI

积极准备下钙化灶 BRS 置入可行

Uso Viable de BRS en Lesiones Calcificadas Con Preparación Agresiva

BRS Use in Calcified Lesions Feasible With Aggressive Preparation

EVERBIO II Published: BVS Matches Leading DES for Midterm Outcomes

BIORESORBABLE VASCULAR SCAFFOLDS A One-day Case-based Technique-oriented Course: A Case with Vessel and - or Lesion Tortuosity

Beyond the Early Stages: Insights from the ASSURE Registry on Bioresorbable Vascular Scaffolds

ASSURE Registry: Angiographic, Clinical Outcomes of BRS Similar to DES at 1 Year

OCT Study Suggests Plaque ‘Capping’ Safer With BRS Than BMS

Con: The Psychological Attraction Will Pass When the Data Emerges!

Pro: Within 10 Years, Most Coronary Intervention Will Use BRS!

TCT 612: Clinical Outcomes in Patients with Calcified Lesions Treated with Bioresorbable Vascular Scaffolds

Status of DCB for PVD and Lessons Learned from the Recent FDA Panel

TCT 611: Multimodality Assessment 12 Months After Implantation of a Bioresorbable Scaffold for the Treatment of Culprit Lesions in Myocardial Infarction

The Emphatic Case for OPCs NOW for New DES Approval in the United States!

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content